US Edition
Bristol Myers Squibb signs $11bn cancer drug deal with BioNTech
- Bristol Myers Squibb signed a global co-development and co-commercialization deal on June 6, 2025, with BioNTech for the PD-L1xVEGF bispecific antibody BNT327.
- Bristol Myers Squibb sought this partnership to accelerate clinical development amid a competitive market for bispecific antibodies following promising data from related drugs like ivonescimab.
- BNT327 is in Phase 3 trials for extensive-stage small cell lung cancer and plans to start late-stage testing for triple-negative breast cancer this year, with over 1,000 patients treated so far.
- Bristol Myers Squibb will pay $1.5 billion upfront, $2 billion in anniversary payments through 2028, and could provide up to $7.6 billion in milestones, sharing profits and costs equally with BioNTech.
- This deal positions Bristol Myers Squibb to potentially replace Opdivo after 2028 exclusivity ends and suggests growing confidence in bispecific antibodies as future cancer immunotherapies.
50 Articles
50 Articles
BioNTech Races to Cash In: $1.5 Billion Poured Into Cancer Drug for mRNA 'Collateral Damage'
BioNTech, the German biotech company that shot to global prominence during the COVID-19 pandemic through its mRNA vaccine partnership with Pfizer, has just signed a $1.5 billion deal with pharmaceutical giant Bristol Myers Squibb. The [...] The post BioNTech Races to Cash In: $1.5 Billion Poured Into Cancer Drug for mRNA ‘Collateral Damage’ appeared first on The People's Voice.
For the development of cancer therapies, the Mainz-based company is allied with the US company Bristol Myers Squibb. This could bring Biontech billions.
Bristol Myers Paying BioNTech Up to $11.1B in Cancer Drug Team-up
Could the world’s best-selling drug have competition on the way? American pharmaceutical giant Bristol Myers Squibb agreed Monday to pay up to $11.1 billion to partner with Germany’s BioNTech and co-develop its next-generation immunotherapy for cancer, which could compete directly with Merck & Co.’s breakthrough treatment Keytruda. Everybody Wants In At the heart of the deal is a relatively new drug technology called PD-1/VEGF bispecific antibod…
Coverage Details
Bias Distribution
- 67% of the sources are Center
To view factuality data please Upgrade to Premium
